Literature DB >> 18474649

Presence of wild-type and attenuated Salmonella enterica strains in brain tissues following inoculation of mice by different routes.

Wendy S Bollen1, Bronwyn M Gunn, Hua Mo, Margarita K Lay, Roy Curtiss.   

Abstract

Salmonella enterica serovar Typhi and Typhimurium vaccine candidates elicit significant immune responses in mice by intranasal (i.n.) immunization. Because of the proximity of the cribriform plate of the ethmoid bone, we were concerned that Salmonella bacteria delivered i.n. might access the brain. Accordingly, wild-type and attenuated (by single and double mutations) strains of S. enterica serovars Typhimurium and Typhi were recovered at low numbers initially from the olfactory lobe and then from the brain for 3 to 4 days after i.n. immunization. This was independent of invA gene function. Although the presence of bacteria in blood 1 to 3 h after i.n. inoculation was sometimes observed, this was infrequent compared to the frequency of bacteria detected in brain tissues. In confirmation of recent observations by Wickham et al. (M. E. Wickham, N. F. Brown, J. Provias, B. B. Finlay, and B. K. Coombes, BMC Infect. Dis. 7:65, 2007) that oral inoculation with wild-type S. enterica serovar Typhimurium strains lead to bacteria in blood with subsequent colonization of brain tissues with neurological symptoms of disease, we found similar results by using the i.n. and intraperitoneal (i.p.) routes of inoculation for wild-type but not for attenuated strains of S. enterica serovar Typhimurium. In contrast, a highly modified attenuated S. enterica serovar Typhimurium strain was not present in brain tissues when administered at higher doses by the oral, i.n., and i.p. routes than the wild-type strain even though the presence of bacteria in blood was detectable 1 to 3 h after inoculation by each of the three routes. Our results indicate that i.n. and possibly even oral delivery of live Salmonella vaccines may be unsafe although it is possible to reduce this risk by appropriate genetic modifications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474649      PMCID: PMC2446729          DOI: 10.1128/IAI.00244-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  The alternative sigma factor katF (rpoS) regulates Salmonella virulence.

Authors:  F C Fang; S J Libby; N A Buchmeier; P C Loewen; J Switala; J Harwood; D G Guiney
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

2.  Studies on lysogenesis. I. The mode of phage liberation by lysogenic Escherichia coli.

Authors:  G BERTANI
Journal:  J Bacteriol       Date:  1951-09       Impact factor: 3.490

3.  Role of RpoS in fine-tuning the synthesis of Vi capsular polysaccharide in Salmonella enterica serotype Typhi.

Authors:  Javier Santander; Soo-Young Wanda; Cheryl A Nickerson; Roy Curtiss
Journal:  Infect Immun       Date:  2006-12-18       Impact factor: 3.441

4.  A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens.

Authors:  J E Galen; O G Gomez-Duarte; G A Losonsky; J L Halpern; C S Lauderbaugh; S Kaintuck; M K Reymann; M M Levine
Journal:  Vaccine       Date:  1997 Apr-May       Impact factor: 3.641

5.  Plasmid-associated virulence of Salmonella typhimurium.

Authors:  P A Gulig; R Curtiss
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

6.  A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization.

Authors:  S Hopkins; J P Kraehenbuhl; F Schödel; A Potts; D Peterson; P de Grandi; D Nardelli-Haefliger
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Salmonella meningitis. Occurrence in an adult.

Authors:  C A Kauffman; R J St Hilaire
Journal:  Arch Neurol       Date:  1979-09

8.  Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.

Authors:  C O Tacket; D M Hone; R Curtiss; S M Kelly; G Losonsky; L Guers; A M Harris; R Edelman; M M Levine
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

9.  CHROMOSOMAL ABERRATIONS ASSOCIATED WITH MUTATIONS TO BACTERIOPHAGE RESISTANCE IN ESCHERICHIA COLI.

Authors:  S R CURTIS
Journal:  J Bacteriol       Date:  1965-01       Impact factor: 3.490

10.  Oral infection of mice with Salmonella enterica serovar Typhimurium causes meningitis and infection of the brain.

Authors:  Mark E Wickham; Nat F Brown; John Provias; B Brett Finlay; Brian K Coombes
Journal:  BMC Infect Dis       Date:  2007-06-27       Impact factor: 3.090

View more
  20 in total

1.  Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system.

Authors:  María Dolores Juárez-Rodríguez; Lourdes T Arteaga-Cortés; Rebin Kader; Roy Curtiss; Josephine E Clark-Curtiss
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge.

Authors:  Christine G Branger; Wei Sun; Ascención Torres-Escobar; Robert Perry; Kenneth L Roland; Jacqueline Fetherston; Roy Curtiss
Journal:  Vaccine       Date:  2010-10-24       Impact factor: 3.641

Review 3.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

4.  Hyaluronidase-Expressing Salmonella Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma.

Authors:  Nancy D Ebelt; Edith Zuniga; Kevin B Passi; Lukas J Sobocinski; Edwin R Manuel
Journal:  Mol Cancer Ther       Date:  2019-11-06       Impact factor: 6.261

5.  Assessment of 2 Salmonella enterica serovar Typhimurium-based vaccines against necrotic enteritis in reducing colonization of chickens by Salmonella serovars of different serogroups.

Authors:  Yanfen Jiang; Raveendra R Kulkarni; Valeria R Parreira; Cornelius Poppe; Kenneth L Roland; John F Prescott
Journal:  Can J Vet Res       Date:  2010-10       Impact factor: 1.310

6.  Immunogenicity of a live recombinant Salmonella enterica serovar typhimurium vaccine expressing pspA in neonates and infant mice born from naive and immunized mothers.

Authors:  Huoying Shi; Shifeng Wang; Kenneth L Roland; Bronwyn M Gunn; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2010-01-06

7.  Construction of recombinant attenuated Salmonella enterica serovar typhimurium vaccine vector strains for safety in newborn and infant mice.

Authors:  Bronwyn M Gunn; Soo-Young Wanda; Dana Burshell; Caihong Wang; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2010-01-06

8.  Evaluation of regulated delayed attenuation strategies for Salmonella enterica serovar Typhi vaccine vectors in neonatal and infant mice.

Authors:  Huoying Shi; Shifeng Wang; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2013-04-24

9.  Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen.

Authors:  Huoying Shi; Javier Santander; Karen E Brenneman; Soo-Young Wanda; Shifeng Wang; Patti Senechal; Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

10.  A colanic acid operon deletion mutation enhances induction of early antibody responses by live attenuated Salmonella vaccine strains.

Authors:  Shifeng Wang; Huoying Shi; Yuhua Li; Zhaoxing Shi; Xin Zhang; Chang-Ho Baek; Tabor Mothershead; Roy Curtiss
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.